Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib/II, Multicenter Open-label Study of CS1001 in Combination With Regorafenib in Patients With Advanced or Refractory Solid Tumors

NCT04200404 is registered in ClinicalTrials.gov with CStone Pharmaceuticals as lead sponsor.

NCT NCT04200404
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04200404 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib/II, Multicenter Open-label Study of CS1001 in Combination With Regorafenib in Patients With Advanced or Refractory Solid Tumors
Lead sponsor
CStone Pharmaceuticals
Phase
Phase 1/2
Overall status
Completed
Start date
December 13, 2019
Completion date
August 18, 2021
Enrollment
19 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced refractory solid tumors